Literature DB >> 23730227

Oncologic management of hereditary colorectal cancer.

George Yacoub1, Srikanth Nagalla, Mebea Aklilu.   

Abstract

Colorectal cancer (CRC) is the second most common cancer in females and the third most common cancer diagnosed in males. Familial CRC comprises ~20 to 30% of all CRC cases. Lynch syndrome (LS), previously called hereditary nonpolyposis CRC (HNPCC), is the most common of the hereditary CRC syndromes. In this review, the oncological management of hereditary colorectal cancer from the medical oncologist perspective is discussed with special emphasis on Lynch syndrome. Lynch syndrome is characterized by the presence of germline mutations in the mismatch repair genes (MMR)-MSH2, MLH1, MSH6, and PMS2. The available data regarding the prognostic role of mismatch repair genes (MMR), the predictive role of MMR genes, and the implications of that in the management of patients with deficient MMR genes (dMMR/MSI-H) tumors including Lynch syndrome patients are also discussed.

Entities:  

Keywords:  Lynch syndrome; chemotherapy; hereditary colorectal cancer; microsatellite instability

Year:  2012        PMID: 23730227      PMCID: PMC3423879          DOI: 10.1055/s-0032-1313783

Source DB:  PubMed          Journal:  Clin Colon Rectal Surg        ISSN: 1530-9681


  27 in total

1.  Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses.

Authors:  M Meyers; M W Wagner; H S Hwang; T J Kinsella; D A Boothman
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

2.  CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.

Authors:  Shuji Ogino; Katsuhiko Nosho; Gregory J Kirkner; Takako Kawasaki; Jeffrey A Meyerhardt; Massimo Loda; Edward L Giovannucci; Charles S Fuchs
Journal:  Gut       Date:  2008-10-02       Impact factor: 23.059

3.  Mismatch repair proficiency and in vitro response to 5-fluorouracil.

Authors:  J M Carethers; D P Chauhan; D Fink; S Nebel; R S Bresalier; S B Howell; C R Boland
Journal:  Gastroenterology       Date:  1999-07       Impact factor: 22.682

4.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.

Authors:  Christine M Ribic; Daniel J Sargent; Malcolm J Moore; Stephen N Thibodeau; Amy J French; Richard M Goldberg; Stanley R Hamilton; Pierre Laurent-Puig; Robert Gryfe; Lois E Shepherd; Dongsheng Tu; Mark Redston; Steven Gallinger
Journal:  N Engl J Med       Date:  2003-07-17       Impact factor: 91.245

5.  Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma.

Authors:  H Elsaleh; B Iacopetta
Journal:  Clin Colorectal Cancer       Date:  2001-08       Impact factor: 4.481

6.  Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group.

Authors:  C I Müller; K Schulmann; A Reinacher-Schick; N Andre; D Arnold; A Tannapfel; H Arkenau; S A Hahn; S H-J Schmoll; R Porschen; W Schmiegel; U Graeven
Journal:  Int J Colorectal Dis       Date:  2008-07-02       Impact factor: 2.571

7.  Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapy.

Authors:  W M Brueckl; C Moesch; T Brabletz; C Koebnick; C Riedel; A Jung; S Merkel; S Schaber; F Boxberger; T Kirchner; W Hohenberger; E G Hahn; A Wein
Journal:  Anticancer Res       Date:  2003 Mar-Apr       Impact factor: 2.480

8.  Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines.

Authors:  Christian N Arnold; Ajay Goel; C Richard Boland
Journal:  Int J Cancer       Date:  2003-08-10       Impact factor: 7.396

9.  Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.

Authors:  Rainer Porschen; Hendrik-Tobias Arkenau; Stephan Kubicka; Richard Greil; Thomas Seufferlein; Werner Freier; Albrecht Kretzschmar; Ullrich Graeven; Axel Grothey; Axel Hinke; Wolff Schmiegel; Hans-Joachim Schmoll
Journal:  J Clin Oncol       Date:  2007-06-04       Impact factor: 44.544

Review 10.  Mismatch repair deficient colorectal cancer in the era of personalized treatment.

Authors:  Madeleine Hewish; Christopher J Lord; Sarah A Martin; David Cunningham; Alan Ashworth
Journal:  Nat Rev Clin Oncol       Date:  2010-02-23       Impact factor: 66.675

View more
  3 in total

Review 1.  Development of cancer-initiating cells and immortalized cells with genomic instability.

Authors:  Ken-Ichi Yoshioka; Yuko Atsumi; Hitoshi Nakagama; Hirobumi Teraoka
Journal:  World J Stem Cells       Date:  2015-03-26       Impact factor: 5.326

2.  Fentanyl inhibits proliferation and invasion of colorectal cancer via β-catenin.

Authors:  Xiu-Lai Zhang; Min-Li Chen; Sheng-Li Zhou
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

Review 3.  Cancer predisposition genes: molecular mechanisms and clinical impact on personalized cancer care: examples of Lynch and HBOC syndromes.

Authors:  Qing Wang
Journal:  Acta Pharmacol Sin       Date:  2015-11-30       Impact factor: 6.150

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.